Press Releases Dicot AB

Equities

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 07/05/2024 BST			5-day change	1st Jan Change
0.2495 ^SEK	+3.96%		-6.38%	-21.54%

05-06	Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-23	Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	CI

Dicot presents interim report Q1 2024	05-06	AQ
Good safety and improved erectile function reported from Dicot's phase 1 study	04-23	AQ
Dicot in preparation for clinical phase 2a trial	04-12	AQ
Reporting from Dicot's phase 1 study end of April	04-05	AQ
BioStock: Dicot's phase I study fully recruited	03-14	AQ
Recruitment completed in Dicot's phase 1 trial	03-11	AQ
Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"	02-29	AQ
Dicot AB Year-End Report 2023	02-26	AQ
BioStock: Good safety profile for Dicot's LIB-01	01-26	AQ
Positive results from the first part of Dicot's phase 1 study	01-23	AQ
Dicot applies for patent covering new manufacturing technology	01-11	AQ
Dicot invited to present at ESSM for the third time	01-05	AQ
BioStock: Interim results from Dicot's phase I study to be released earlier than expected	12-20	AQ
Partial results from Dicot's phase 1 trial to be presented early next year	12-15	AQ
BioStock: Great interest in Dicot's LIB-01	11-30	AQ
Dicot gains significant interest at North America's major sexual medicine congress	11-24	AQ
Dicot's warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost	11-17	AQ
Dicot initiates repeated dosing in its clinical study	11-14	AQ
Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023	11-02	AQ
The exercise period for warrants TO5 in Dicot starts today	11-01	AQ

No results for this search